loss of esterase activity per se but to loss of some other function of the esterase protein molecule when it is phosphorylated. It is hoped that comparison of the behaviour of the purified site protein when it is phosphorylated or sulphonated in vitro may lead to further understanding of the whole disturbed process which leads to degeneration of the axon.
Dr L W Duchen (Department ofNeuropathology, Institute ofPsychiatry, De Crespigny Park, London SE5) Motor Nerve Growth Induced by Botulinum Toxin as a Regenerative Phenomenon Botulinum toxin exerts its effects on the nervous system in a highly specific manner. In both voluntary and autonomic systems transmission at cholinergic nerve terminals is blocked, causing flaccid paralysis of skeletal muscle and parasympathetic failure. If an injection of botulinum toxin is made directly into a muscle of an experimental animal it is possible to study the effects of the toxin through successive stages of paralysis and recovery, provided that the dose of toxin is small enough to cause only local effects and the animal can survive the transient general toxic effects. In the experiments which I have carried out a sublethal dose of Type A botulinum toxin was injected into calf muscles of one hindleg in mice. Within about twentyfour hours the muscles of the leg became paralysed and recovered only after several weeks (Duchen & Strich 1968 ). This paper is concerned with changes which take place in the motor nerves of the affected muscles since it seems that these changes are the means by which function is restored.
For the first few days after the onset of muscle paralysis no abnormalities were found in the motor nerve terminals or in myelinated preterminal nerve fibres with either light or electron microscopy. The first light microscopic changes in the morphology of motor nerves were found in the slow (red) soleus 6-7 days after the injection of toxin (Duchen 1970a) , but were seen after four days with the electron microscope (Duchen 1971) . It was found that axonal sprouts grew out from the intact nerve terminals in the motor end-plates. For several weeks these motor nerve sprouts grew along and branched across the muscle fibres which became progressively more atrophied. With electron microscopy it was found that the sprouting axons were wrapped in processes of Schwann cells which were interposed between axolemma and sarcolemma, and the sarcolemma showed no subneural folds. Enzyme histochemical studies showed that while true (acetyl) cholinesterase was localized to the subneural folds of the original end-plates, pseudo (butyryl) cholinesterase was found along the axonal sprouts mainly between axon and Schwann cells. The growing axons contained neurofilaments, mitochondria and vesicles. About two to three weeks after the commencement of nerve sprouting in soleus, the muscle fibres were no longer paralysed and again increased in size. At this time motor nerve growth ceased and electron microscopy showed that close contacts between axolemma and sarcolemma were formed at which vesicles became aggregated. No subneural folds were present at these new neuromuscular junctions and it took several more weeks before shallow and irregular folds were formed. Over the next few months the subneural folds became steadily more like the normal. The new neuromuscular junctions were irregular in size and abnormal in distribution, being scattered along muscle fibres randomly. In the superficial part of the gastrocnemius which contains fast (white) muscle fibres, the axonal sprouting began about three to four weeks after the injection of the toxin (several weeks later than in soleus), but once the sprouting had commenced the sequence of events was similar in the two muscles. However, the muscle fibres of gastrocnemius became more severely atrophied than those of soleus, probably because of the prolonged delay in the onset of nerve sprouting and in the formation of new neuromuscular junctions.
In other experiments (unpublished) the effect of varying the dose of toxin was investigated. Three different doses of toxin, each contained in the same volume of buffer, were injected. The highest dose was approximately at the LD50 level while the lowest dose was one-twentieth of that level. The higher the dose of toxin the more severe was the degree of paralysis and atrophy and the more profuse and extensive was the nerve sprouting.
Further experiments were carried out to study the effect of nerve crush and regeneration on the innervation of muscles paralysed by sequence ofevents at the motor end-plate after the injection ofbotulinum toxin. In (a) the toxin has becomefixed to the motor nerve terminal and is represented by the cross-hatching. Axonal sprouting commences from the terminal (b) and the growing axon is wrapped in processes ofSchwann cells which separate itfrom the musclefibre. The bound toxin is gradually diluted out (c) and the axonforms new contacts with the musclefibre at some distancefrom the site ofthe original end-plate. The contacts are at first loose and without subneuralfolds ofsarcolemma but later become close and subneuralfolds are formed (d) botulinum toxin (Duchen 1970b) . Botulinum toxin was injected into the leg muscles and after the onset of paralysis the sciatic nerve was crushed and then allowed to regenerate. In these animals the axons distal to the lesion degenerated but regenerated from their intact proximal stumps and re-innervated the original end-plates. Within seven to ten days neuromuscular function was restored. The sequence of events was similar to that occurring after nerve crush in normal animals. The muscles did not become atrophied and the axons did not sprout beyond the end-plate excessively, in marked contrast to the picture found after the injection of toxin alone.
There are several points of interest in the consideration of the motor nerve sprouting induced by botulinum toxin. (1) The toxin causes paralysis without the destruction of motor axons or terminals. (2) Once motor nerve sprouting has begun it continues for several weeks before new end-plates are formed, unlike the re-innervation of structurally denervated muscle fibres on which a new motor nerve rapidly forms a functioning end-plate. (3) The nerve sprouting found after the injection of toxin seems to be proportional to the dose of toxin injected. (4) The nerve sprouting beyond the motor end-plates is abolished if, after the injection of toxin, the nerve is crushed and then allowed to regenerate. This implies that the degeneration and removal of the original blocked nerve terminals after the crush injury has allowed the removal of whatever it was that impaired neuromuscular transmission.
A hypothesis to account for the sequence of events might be summarized as in Fig 1. The toxin becomes fixed in an unknown way either to the pre-synaptic axolemma or to some component of the axoplasm of the motor nerve terminal, and there remains in its bound form blocking neuromuscular transmission. Only after sufficient new axonal tissue is formed by the growing motor nerve can transmission begin again at points along the axon where bound toxin has been 'diluted out'. The nerve growth induced by botulinum toxin can thus be regarded as a form of regeneration of the motor neurone, differing from previously studied forms of regeneration in the nervous system in that there has been no structural loss of tissue but only a loss of function within the nerve terminal. The mechanism which initiates motor nerve growth is still not known either in the present experimental situation or after axonal injury and it seems likely that some factor is common to both. Since motor nerve growth does not normally occur once neuromuscular connexions are formed it may be that contact with the muscle fibre permits an inhibitory mechanism to operate. Any interruption of this contact, whether structural or functional, may be responsible for the initiation of events leading to new nerve growth. During the last sixteen years there has been a marked change in attitudes of investigators towards the nature and extent of the information required before a compound intended for human or veterinary use is given for the first time to volunteers, patients or livestock. Twenty years ago it was commonplace for a research worker merely to investigate the desired pharmacological and chemotherapeutic properties in
